Opendata, web and dolomites

HPV OncoPredict SIGNED

A Groundbreaking Stand-Alone Diagnostic Kit to Predict Human Papilloma Virus Infections Evolving into Cervical Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HPV OncoPredict project word cloud

Explore the words cloud of the HPV OncoPredict project. It provides you a very rough idea of what is the project "HPV OncoPredict" about.

human    young    hrhpv    huge    disease    detecting    stand    smears    causing    market    oncopredict    despite    samples    biomarkers    cancer    overwhelming    frequently    diagnosis    screening    persistent    leaders    cervical    infected    315    patient    triage    competitor    million    people    infection    stratify    hiantis    alone    identification    accurate    10    benefit    detection    feed    treatment    acids    pap    curable    disruptive    nucleic    innovative    companies    shape    kills    technologies    hpv    earlier    single    primary    responsible    undergo    reliably    manner    risk    truly    patented    250    smear    women    capacity    patients    ivd    preventable    genefirst    guidelines    collected    performed    recommended    tests    oncogenic    ahead    strategies    cc    prevention    replace    vaccination    viral    detected    papillomavirus    starting    clinician    formed    diagnostic    genotypes    subsequent    positive    opinion    cellular    annually    cytology    population    self    device    feared    healthcare   

Project "HPV OncoPredict" data sheet

The following table provides information about the project.

Coordinator
GENEFIRST LIMITED 

Organization address
address: BUILDING E5 CULHAM SCIENCE CENTRE
city: ABINGDON
postcode: OX14 3DB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.genefirst.com/hpv-oncopredict
 Total cost 2˙945˙000 €
 EC max contribution 2˙923˙061 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENEFIRST LIMITED UK (ABINGDON) coordinator 1˙700˙000.00
2    HIANTIS SRL IT (MILAN) participant 1˙223˙061.00

Map

 Project objective

Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. It is preventable, by HPV vaccination and the implementation of population screening programmes, and it is curable if detected and treated early. Despite overwhelming evidence that detection of viral nucleic acids (HPV testing) in cervical cellular samples allows earlier detection of CC as compared to cytology (Pap smear), it is feared that its use as a stand-alone test in CC screening would be responsible for over-diagnosis and over-treatment.

HPV OncoPredict is an innovative diagnostic device (IVD) capable of detecting all oncogenic hrHPV genotypes frequently causing cervical infection as well as allowing to accurate identification those 10% of infected women who are truly at risk of developing cervical cancer. With the use of novel viral biomarkers, HPV OncoPredict, starting from a single self- or clinician-collected cellular sample, will enable women to undergo both primary cervical screening and, if HPV-positive, subsequent triage. HPV OncoPredict will allow HPV testing to reliably replace Pap smears in cervical cancer prevention, as recently recommended by European guidelines, being based on a disruptive technology ahead of any competitor’s product and supported by key opinion leaders.

The HPV testing market is huge (€315 M) with around 100 million tests performed each year. The consortium formed by GeneFirst and Hiantis, both highly innovative companies with patented technologies, has the capacity to bring HPV OncoPredict to success. HPV OncoPredict will not only shape the manner in which we stratify women at risk of developing cervical cancer, but also provide an accurate and cost effective test of disease to benefit patients. More importantly, it will feed into how healthcare systems implement screening strategies to benefit patient pathways.

 Publications

year authors and title journal last update
List of publications.
2018 M. Arbyn, E. Peeters, I. Benoy, D. Vanden Broeck, J. Bogers, P. De Sutter, G. Donders, W. Tjalma, S. Weyers, K. Cuschieri, M. Poljak, J. Bonde, C. Cocuzza, F.H. Zhao, S. Van Keer, A. Vorsters
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
published pages: 52-56, ISSN: 1386-6532, DOI: 10.1016/j.jcv.2018.08.006
Journal of Clinical Virology 107 2019-11-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HPV ONCOPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HPV ONCOPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More